# Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

> **NCT07317609** · PHASE1 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel
- **PROCEDURE:** Endoscopic resection
- **PROCEDURE:** Esophagectomy
- **RADIATION:** Concurrent chemoradiation

## Key facts

- **NCT ID:** NCT07317609
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07317609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07317609, "Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07317609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*